Moving Targets
Establishing accurate estimates of HIV incidence rates are critical to the success of prevention trials
Vol. 11, No. 3, May-June 2007
Moving Targets, Perspective: HIV Controllers: Can the Human Genome Project Advance AIDS, Vaccine Development?, One-Two Combination, Vaccine Briefs
One-Two Combination
Heterologous prime-boost is currently the regimen of choice for many AIDS vaccine approaches, even though exactly how it works is still far from clear
Perspective: HIV Controllers: Can the Human Genome Project Advance AIDS Vaccine Development?
By Toshiyuki Miura, Kholiswa Ngumbela, Danni Ramduth, Florencia Pereyra, and Bruce Walker*
At the pivotal United Nations General Assembly Special Session on HIV (UNGASS) meeting in New York in June 2001, there was an urgent call to action regarding the expanding HIV pandemic, including increased treatment access for HIV-infected persons worldwide.
Vaccine Briefs
First Clinical Trial With a Novel Adenovirus Vector Begins